Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency

por Cheng, Le, Zhou, Zongxiang, Flesken-Nikitin, Andrea, Toshkov, Ilia A., Wang, Wei, Camps, Jordi, Ried, Thomas, Nikitin, Alexander Yu.
Publicado 2010

Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice

por Kojouharov, Bojidar M., Brackett, Craig M., Veith, Jean M., Johnson, Christopher P., Gitlin, Ilya I., Toshkov, Ilia A., Gleiberman, Anatoli S., Gudkov, Andrei V., Burdelya, Lyudmila G.
Publicado 2014

The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates

por Krivokrysenko, Vadim I., Toshkov, Ilia A., Gleiberman, Anatoli S., Krasnov, Peter, Shyshynova, Inna, Bespalov, Ivan, Maitra, Ratan K., Narizhneva, Natalya V., Singh, Vijay K., Whitnall, Mark H., Purmal, Andrei A., Shakhov, Alexander N., Gudkov, Andrei V., Feinstein, Elena
Publicado 2015

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

por Mett, Vadim, Kurnasov, Oleg V., Bespalov, Ivan A., Molodtsov, Ivan, Brackett, Craig M., Burdelya, Lyudmila G., Purmal, Andrei A., Gleiberman, Anatoli S., Toshkov, Ilia A., Burkhart, Catherine A., Kogan, Yakov N., Andrianova, Ekaterina L., Gudkov, Andrei V., Osterman, Andrei L.
Publicado 2021